Insight Molecular Diagnostics, Inc. (IMDX)
4.14
+0.13
(+3.24%)
USD |
NASDAQ |
Sep 22, 16:00
4.115
-0.02
(-0.60%)
After-Hours: 20:00
Insight Molecular Diagnostics Enterprise Value : 119.20M for Sept. 22, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 22, 2026 | 119.20M |
| September 21, 2026 | 114.96M |
| September 18, 2026 | 114.63M |
| September 17, 2026 | 113.00M |
| September 16, 2026 | 100.93M |
| September 15, 2026 | 115.28M |
| September 14, 2026 | 115.28M |
| September 11, 2026 | 121.16M |
| September 10, 2026 | 113.98M |
| September 09, 2026 | 117.89M |
| September 08, 2026 | 123.44M |
| September 04, 2026 | 118.87M |
| September 03, 2026 | 118.55M |
| September 02, 2026 | 114.96M |
| September 01, 2026 | 109.41M |
| August 31, 2026 | 112.02M |
| August 28, 2026 | 118.87M |
| August 27, 2026 | 124.09M |
| August 26, 2026 | 124.42M |
| August 25, 2026 | 128.99M |
| August 24, 2026 | 125.07M |
| August 21, 2026 | 125.72M |
| August 20, 2026 | 124.42M |
| August 19, 2026 | 127.03M |
| August 18, 2026 | 123.77M |
| Date | Value |
|---|---|
| August 17, 2026 | 123.44M |
| August 14, 2026 | 125.07M |
| August 13, 2026 | 105.17M |
| August 12, 2026 | 130.94M |
| August 11, 2026 | 128.66M |
| August 10, 2026 | 139.75M |
| August 07, 2026 | 141.71M |
| August 06, 2026 | 140.73M |
| August 05, 2026 | 147.25M |
| August 04, 2026 | 151.17M |
| August 03, 2026 | 148.23M |
| July 31, 2026 | 135.84M |
| July 30, 2026 | 134.21M |
| July 29, 2026 | 126.70M |
| July 28, 2026 | 134.53M |
| July 27, 2026 | 137.47M |
| July 24, 2026 | 138.77M |
| July 23, 2026 | 145.95M |
| July 22, 2026 | 146.93M |
| July 21, 2026 | 147.25M |
| July 20, 2026 | 142.03M |
| July 17, 2026 | 138.77M |
| July 16, 2026 | 137.79M |
| July 15, 2026 | 141.38M |
| July 14, 2026 | 129.64M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Perspective Therapeutics, Inc. | 104.78M |
| Agenus, Inc. | 635.42M |
| Amgen, Inc. | 265.09B |
| Anika Therapeutics, Inc. | 266.41M |
| BioCryst Pharmaceuticals, Inc. | 2.725B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -11.26M |
| Revenue (Quarterly) | 0.239M |
| Total Expenses (Quarterly) | 11.50M |
| EPS Diluted (Quarterly) | -0.3064 |
| Gross Profit Margin (Quarterly) | -202.5% |
| Profit Margin (Quarterly) | -4.71K% |
| Earnings Yield | -35.88% |
| Normalized Earnings Yield | -28.82 |